NasdaqGS:AGIOBiotechs
What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders
Agios Pharmaceuticals recently reported that, following a pre-supplemental New Drug Application meeting, the FDA encouraged it to seek U.S. accelerated approval of mitapivat for sickle cell disease and submit a confirmatory trial proposal based on the RISE UP Phase 2 and 3 data package.
The move to accelerated approval, with a new confirmatory trial endpoint and operating expenses expected to remain roughly flat versus 2025, could reshape how investors view Agios’s risk–reward profile around...